SCHEMBL2664643

SCHEMBL2664643

COC(=O)c1ccc(NC(=O)c2cc(OCc3ccccc3Cl)cc(OCc3ccccc3Cl)c2)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.57
MEN1 O00255 3/20 0.57
POLB P06746 2/20 0.57
CYP1A2 P05177 2/20 0.57
GAA P10253 1/20 0.57
CYP2C9 P11712 1/20 0.57
HPGD P15428 1/20 0.57
GFER P55789 1/20 0.56
LMNA P02545 1/20 0.49
NR4A2 P43354 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
MAOB P27338 2/20 0.46
MAOA P21397 1/20 0.46
GCK P35557 1/20 0.46
CYP2C19 P33261 1/20 0.44
HDAC8 Q9BY41 2/20 0.43
ADAM17 P78536 1/20 0.42
SLC26A4 O43511 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13678465 0.90 POLB (0.47) KMT2AMEN1POLBCYP1A2GAA
SCHEMBL2664642 0.89 NR4A2 (0.54) KMT2AMEN1POLBCYP1A2GAA
SCHEMBL1796005 0.81 NR4A2 (0.60) KMT2AMEN1HPGDLMNANR4A2
SCHEMBL2664907 0.81 RAB9A (0.56) KMT2AMEN1POLBHPGDLMNA
SCHEMBL2664634 0.76 GCK (0.54) KMT2AMEN1HPGDLMNANR4A2
SCHEMBL2664599 0.76 GCK (0.56) KMT2AMEN1HPGDNR4A2NPC1
SCHEMBL2664904 0.75 KDM4E (0.55) KMT2AMEN1POLBGAAHPGD
SCHEMBL1792201 0.74 GCK (0.64) KMT2AMEN1NR4A2NPC1RAB9A
SCHEMBL2664901 0.73 NR4A2 (0.66) GAAHPGDLMNANR4A2NPC1
SCHEMBL2664903 0.73 NPC1 (0.55) KMT2AMEN1LMNANR4A2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed
EP-1568367-B1 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2007-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 KMT2A 1974/4885MEN1 1260/4885POLB 3300/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 KMT2A 1974/4885MEN1 1260/4885POLB 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.